Live Breaking News & Updates on மூலக்கூறு கரைப்பு

Stay informed with the latest breaking news from மூலக்கூறு கரைப்பு on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in மூலக்கூறு கரைப்பு and stay connected to the pulse of your community

Molecular Partners AG: Molecular Partners to Present Data from Localized Immune Agonist (MP0317), T-cell Engager, and Peptide-MHC Immunotherapy Programs at AACR Annual Meeting

(2)
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE /
March 10, 2021. Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the upcoming presentation of four posters with data supporting three of the company's immunotherapy programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting running April 10-15, 2021.
The accepted research describes multiple aspects of validation for the unique mechanisms of these therapies in development for treating a wide range of tumor types.
Accepted abstract titles include:
MP0317 (targeting CD40 and FAP)
MP0317, a FAPxCD40 targeting multi-specific DARPin® therapeutic, drives immune activation and leads to macrophage repolarization in vitro and ex vivo

Zurich , Zusz , Switzerland , United-states , American , Shai-biran , Prodrug-darpin , Seth-lewis , Thomas-schneckenburger , American-academy-for-cancer-research , Company-on-twitter-at-molecularprtnrs , American-academy

New biosensor measures extracellular hydrogen peroxide levels with nanometer-resolution

New biosensor measures extracellular hydrogen peroxide levels with nanometer-resolution
Several processes in the human body are regulated by biochemical reactions involving hydrogen peroxide (H
2O
2).
2O
2 is generally toxic because of its oxidant character. The latter means that it converts (oxidizes) biochemical molecules like proteins and DNA.
The oxidizing property of H
2O
2 is of potential therapeutic relevance for cancer, though: deliberately causing tumor cells to increase their H
2O
2 concentration would be a way to destroy them. In light of this, but also for monitoring pathologies associated with H
2O
2 overproduction, it is crucial to have a means to reliably quantify hydrogen peroxide concentrations in the extracellular environment.

Leonardo-puppulin , Emily-henderson , Nano-life-science-institute , Kanazawa-university , Biosensor , Hydrogen-peroxide , Cancer , Cell , Compound , Conjugation , Dna , Frequency

Parkinson's UK, University of Sheffield to develop new Parkinson's drug

Parkinson’s UK, University of Sheffield to develop new Parkinson’s drug
Parkinson's UK, the largest charitable funder of Parkinson's research in Europe, is investing up to £1.2 million into a pioneering one-year project in partnership with the University of Sheffield.
The project aims to refine a molecule that could be developed into a drug to protect dopamine-producing brain cells and slow down the progression of Parkinson's.
The funding boost comes via the charity's Parkinson's Virtual Biotech initiative, which is plugging the funding gap in drug development and fast-tracking the development of new treatments for people with Parkinson's.
Scientists at the University of Sheffield's Institute of Translational Neuroscience (SITraN) and Parkinson's UK have been developing molecules that can boost the function of the brain's energy-producing mitochondria, to halt Parkinson's - something no treatment can currently do.

United-kingdom , Heather-mortiboys , Arthur-roach , Emily-henderson , Institute-of-translational-neuroscience , Research-at-parkinson-united-kingdom , University-of-sheffield , Virtual-biotech , Translational-neuroscience , United-kingdom-senior-fellowship , United-kingdom-drug-discovery , Senior-lecturer

Molecular Partners AG: Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers

Molecular Partners AG: Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers
Predictable exposure seen post administration, confirming the expected half-life of 2-3 weeks
Global phase 2/3 registrational study planned to initiate in Q2 2021
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE /
March 9, 2021 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced initial results from its ongoing phase 1 study of its first tri-specific COVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers.
In the placebo-controlled phase 1 study, healthy volunteers were randomized 3:1 to receive an infusion of ensovibep, or placebo, respectively. Two dosing cohorts have been fully enrolled and received a single infusion of 3mg or 9mg per kilogram body weight, with 8 patients per dose cohort (16 total: 12 active, 4 placebo). In each of these cohorts, ensovibep was seen to be safe and well tolerated, with no significant adverse events reported. Preliminary results showed extended exposure of the DARPin® candidate in serum, with a half-life of 2-3 weeks, as was expected from preclinical experiments. These data confirm the systemic administration of a multi-specific DARPin® antiviral therapy to be safe and well tolerated, and support advanced plans for additional clinical work in positively diagnosed patients.

Zurich , Zusz , Switzerland , United-kingdom , Swiss , Shai-biran , Nicolas-leupin , Seth-lewis , Thomas-schneckenburger , Twitter , Company-on-twitter-at-molecularprtnrs , Novartis

New technique helps image biological samples at the microscopic level

New technique helps image biological samples at the microscopic level
Researchers have developed a spectroscopic microscope to enable optical measurements of molecular conformations and orientations in biological samples. The novel measurement technique allows researchers to image biological samples at the microscopic level more quickly and accurately.
The new instrument is based on the discrete frequency infrared spectroscopic imaging technique developed by researchers at the Beckman Institute for Advanced Science and Technology at the University of Illinois Urbana-Champaign.
This project is about bringing the study of molecular chirality into the microscopic domain."
Rohit Bhargava, Professor, Bioengineering, Director, Cancer Center, Illinois
Molecular chirality refers to the spatial orientation of atoms in molecules or multimolecule assemblies. In biological systems, one molecule may elicit a cellular response, while its mirror image could be inactive or even toxic. While vibrational circular dichroism can be employed to help determine a molecule's chemical structure and orientation, VCD measurements are time-intensive and could not previously be used to image complex biological systems or solid tissues samples.

Illinois , United-states , University-of-illinois , Beckman-institute , Kevin-yeh , Rohit-bhargava , Emily-henderson , Beckman-institute-for-advanced-science , Structures-laboratory , Cancer-center , University-of-illinois-urbana-champaign , Advanced-science

Scientists develop RNA-based therapeutic strategy for Charcot-Marie Tooth disease

Scientists develop RNA-based therapeutic strategy for Charcot-Marie Tooth disease
Charcot-Marie Tooth disease is the most common hereditary neurological disease in the world. It affects the peripheral nerves and causes progressive paralysis of the legs and hands.
No treatment is currently available to fight this disease, which is due to the overexpression of a specific protein. Scientists from the CNRS, INSERM, the AP-HP and the Paris-Saclay and Paris universities have developed a therapy based on degrading the coding RNA for this protein in mice. Their work is patented and was published on 9 March 2021 in
Communications Biology.
In molecular biology, transcription is when a DNA molecule is copied to make an RNA molecule. This RNA molecule is then "translated" into a protein, which can perform different functions within the body's cells. When a specific protein called PMP22 is made twice as much as normal, it causes type 1A of genetic Charcot-Marie Tooth disease to develop. This overproduction leads to gradual paralysis of the legs and hands.

Saclay , France-general , France , Paris , French , Emily-henderson , Communications-biology , Marie-tooth , Charcot-marie-tooth , Rna , Dna , Molecular-biology

Funnel-web spider venom may one day help save the lives of heart transplant patients

Funnel-web spider venom may one day help save the lives of heart transplant patients
Posted
TueTuesday 9
updated
WedWednesday 10
The funnel-web is Australia's most venomous spider.
(
Share
Print text only
Cancel
Striding along a sandy track, a group of scientists is doing something kids are warned not to do: looking for funnel-web spiders.
Leading the pack, known as the "bugs-and-drugs squad", is biochemist Glenn King from the University of Queensland, who has built a career unpicking the chemical composition of Australia's venomous creatures.
He and his team have come to K'gari — the place you may know as Fraser Island — looking for a special kind of treasure in funnel-web venom: a miracle molecule.

Australia , Brisbane , Queensland , Fraser-island , Trinidad-and-tobago , Trinidadian , Sarah-scheuer , Sam-nixon , Natalie-saez , Glenn-king , Victor-chang-cardiac-research-institute , University-of-queensland

Narrowing down on small molecular inhibitors of SARS-CoV-2 key protease

Narrowing down on small molecular inhibitors of SARS-CoV-2 key protease
A recent methodological study by researchers from the University of Luxembourg shows that the combination of virtual screening approaches, molecular dynamics simulations and machine learning can substantially facilitate small molecule screening investigations targeted at key SARS-CoV-2 viral proteins. Their findings are currently available on the
bioRxiv* preprint server.
The coronavirus disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still a major challenge for healthcare systems and economies worldwide. And while vaccines are being rolled out all over the world, the available drug-based therapies are still lacking.

Luxembourg , Ganesh-babu-manoharan , Daniel-abankwa , Enrico-glaab , University-of-luxembourg , Coronavirus-disease-covid-19 , Sars , Sars-cov-2 , Compound , Corona-virus , Health-care , In-vitro

New, efficient method facilitates antibody development

In recent years, therapeutic antibodies have transformed the treatment of cancer and autoimmune diseases.

Sweden , Jenny-mattsson , Emily-henderson , Nature-communications , Lund-university , Bioinvent-international , Department-of-hematology , Foundation-for-strategic-research , Doctoral-student , Transfusion-medicine , Antibody , Drugs

Study identifies potential therapeutic target for non-alcoholic fatty liver disease

Study identifies potential therapeutic target for non-alcoholic fatty liver disease
An international team of researchers has identified the CNNM4 protein as a key regulator of magnesium in the liver and potential therapeutic target for non-alcoholic fatty liver disease, according to a study published in the
Journal of Hepatology.
Non-alcoholic steatohepatitis, a form of fatty liver disease characterized by inflammation and liver fibrosis, is associated with obesity and has a worldwide prevalence of 1.7 billion people.
Unhealthy nutritional habits and dietary imbalances are recognized as causes of many diseases. Magnesium is widely available in both plant and animal foods; most vegetables, legumes, peas, beans, and nuts are rich in magnesium, as are some seafood and spices. In recent years, there has been growing concern about inadequate magnesium intake in the general population. According to the National Health and Nutrition Examination Survey (NHANES), 79% of U.S. adults do not meet the recommended intake of magnesium.

Spain , Daniela-buccella , Jorge-simon , Malu-mart , Emily-henderson , Nutrition-examination-survey , National-health , Liver-disease-laboratory-at-spain , York-university , Liver-disease-laboratory , Enfermedades-hep , Silence-therapeutic